Ping An Healthcare and Technology Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Ping An Healthcare and Technology wird ein jährliches Gewinn- und Umsatzwachstum von 53.6% bzw. 7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 51.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 0.9% betragen.
Wichtige Informationen
53.6%
Wachstumsrate der Gewinne
51.6%
EPS-Wachstumsrate
| Consumer Retailing Gewinnwachstum | 28.0% |
| Wachstumsrate der Einnahmen | 7.0% |
| Zukünftige Eigenkapitalrendite | 0.9% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 15 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Ping An Healthcare and Technology Company Limited (HKG:1833) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Nov 17
Ping An Healthcare and Technology Company Limited (HKG:1833) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
Sep 27Ping An Healthcare and Technology Company Limited (HKG:1833) Shares Could Be 49% Below Their Intrinsic Value Estimate
Sep 20Ping An Healthcare and Technology Company Limited's (HKG:1833) Share Price Not Quite Adding Up
Jul 17Revenues Not Telling The Story For Ping An Healthcare and Technology Company Limited (HKG:1833)
Apr 17Ping An Healthcare and Technology (HKG:1833) Is In A Strong Position To Grow Its Business
Mar 20Calculating The Fair Value Of Ping An Healthcare and Technology Company Limited (HKG:1833)
Jan 12Getting In Cheap On Ping An Healthcare and Technology Company Limited (HKG:1833) Is Unlikely
Dec 22We're Hopeful That Ping An Healthcare and Technology (HKG:1833) Will Use Its Cash Wisely
Sep 27A Look At The Intrinsic Value Of Ping An Healthcare and Technology Company Limited (HKG:1833)
Sep 10When Should You Buy Ping An Healthcare and Technology Company Limited (HKG:1833)?
Aug 02Here's Why We're Not Too Worried About Ping An Healthcare and Technology's (HKG:1833) Cash Burn Situation
Jun 26Ping An Healthcare and Technology Company Limited's (HKG:1833) Share Price Could Signal Some Risk
Jun 07Is There An Opportunity With Ping An Healthcare and Technology Company Limited's (HKG:1833) 46% Undervaluation?
Apr 04Should You Think About Buying Ping An Healthcare and Technology Company Limited (HKG:1833) Now?
Feb 16We Think Ping An Healthcare and Technology (HKG:1833) Can Afford To Drive Business Growth
Jan 23A Look At The Fair Value Of Ping An Healthcare and Technology Company Limited (HKG:1833)
Jan 02Companies Like Ping An Healthcare and Technology (HKG:1833) Are In A Position To Invest In Growth
Oct 11Estimating The Fair Value Of Ping An Healthcare and Technology Company Limited (HKG:1833)
Sep 14Companies Like Ping An Healthcare and Technology (HKG:1833) Are In A Position To Invest In Growth
Jun 22We're Hopeful That Ping An Healthcare and Technology (HKG:1833) Will Use Its Cash Wisely
Mar 01We're Not Very Worried About Ping An Healthcare and Technology's (HKG:1833) Cash Burn Rate
Nov 13Are Ping An Healthcare and Technology Company Limited (HKG:1833) Investors Paying Above The Intrinsic Value?
Oct 18Companies Like Ping An Healthcare and Technology (HKG:1833) Are In A Position To Invest In Growth
Aug 05Are Ping An Healthcare and Technology Company Limited (HKG:1833) Investors Paying Above The Intrinsic Value?
Jul 10We Think Ping An Healthcare and Technology (HKG:1833) Can Afford To Drive Business Growth
Apr 04If You Had Bought Ping An Healthcare and Technology (HKG:1833) Shares A Year Ago You'd Have Earned 47% Returns
Feb 28Are Institutions Heavily Invested In Ping An Healthcare and Technology Company Limited's (HKG:1833) Shares?
Jan 24
We Think Ping An Healthcare and Technology (HKG:1833) Can Easily Afford To Drive Business Growth
Dec 29Does This Valuation Of Ping An Healthcare and Technology Company Limited (HKG:1833) Imply Investors Are Overpaying?
Dec 03Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 5,590 | 252 | 306 | 454 | 11 |
| 12/31/2025 | 5,445 | 168 | 189 | 352 | 13 |
| 12/31/2024 | 4,600 | 118 | 74 | 68 | 13 |
| 6/30/2024 | 4,545 | -21 | -387 | -351 | N/A |
| 3/31/2024 | 4,609 | -172 | -356 | -317 | N/A |
| 12/31/2023 | 4,674 | -323 | -326 | -283 | N/A |
| 9/30/2023 | 5,135 | -370 | -577 | -536 | N/A |
| 6/30/2023 | 5,596 | -418 | -829 | -789 | N/A |
| 3/31/2023 | 5,901 | -527 | -837 | -800 | N/A |
| 12/31/2022 | 6,205 | -636 | -845 | -811 | N/A |
| 9/30/2022 | 6,276 | -879 | -1,042 | -992 | N/A |
| 6/30/2022 | 6,347 | -1,121 | -1,239 | -1,174 | N/A |
| 3/31/2022 | 6,841 | -1,330 | -1,366 | -1,288 | N/A |
| 12/31/2021 | 7,334 | -1,538 | -1,492 | -1,403 | N/A |
| 9/30/2021 | 7,636 | -1,576 | -1,319 | -1,232 | N/A |
| 6/30/2021 | 7,938 | -1,614 | -1,145 | -1,060 | N/A |
| 3/31/2021 | 7,402 | -1,281 | -1,160 | -1,081 | N/A |
| 12/31/2020 | 6,866 | -948 | -1,175 | -1,102 | N/A |
| 9/30/2020 | 6,203 | -812 | -822 | -730 | N/A |
| 6/30/2020 | 5,539 | -675 | -469 | -358 | N/A |
| 3/31/2020 | 5,302 | -704 | -553 | -431 | N/A |
| 12/31/2019 | 5,065 | -734 | -637 | -504 | N/A |
| 9/30/2019 | 4,777 | -737 | -856 | -682 | N/A |
| 6/30/2019 | 4,488 | -740 | -1,075 | -859 | N/A |
| 3/31/2019 | 3,913 | -826 | -1,179 | -972 | N/A |
| 12/31/2018 | 3,338 | -912 | -1,283 | -1,085 | N/A |
| 9/30/2018 | 3,082 | -1,182 | -1,125 | -1,007 | N/A |
| 6/30/2018 | 2,542 | -990 | -866 | -827 | N/A |
| 3/31/2018 | 2,205 | -996 | N/A | -655 | N/A |
| 12/31/2017 | 1,868 | -1,002 | N/A | -484 | N/A |
| 9/30/2017 | 1,319 | -641 | N/A | -531 | N/A |
| 12/31/2016 | 601 | -758 | N/A | -263 | N/A |
| 12/31/2015 | 279 | -324 | N/A | -45 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 1833 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.3%).
Ertrag vs. Markt: 1833 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: 1833 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: 1833Die Einnahmen des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (7.8% pro Jahr).
Hohe Wachstumseinnahmen: 1833Die Einnahmen des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 1833Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (0.9%).